Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth [Seeking Alpha]
Cytek Biosciences, Inc. (CTKB)
Company Research
Source: Seeking Alpha
Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier. Over time, CTKB should continue growing its reagents and service businesses while creating higher-margin recurring revenue. Ultimately, I think the company's valuation multiples and ample cash runway support a bullish rating. Thus, I rate it a 'Buy' at these levels. Inna Dodor/iStock via Getty Images Cytek Biosciences ( CTKB ) is a biotech that has a platform for cell analysis. Essentially, they leverage their Full Spectrum Profiling (FSP) spectral cytometry technology to capture the full emission spectrum of each fluorochrome. This basically produces higher-parameter and more This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies me
Show less
Read more
Impact Snapshot
Event Time:
CTKB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTKB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTKB alerts
High impacting Cytek Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CTKB
News
- Cytek Biosciences (NASDAQ:CTKB) was given a new $6.00 price target on by analysts at Morgan Stanley.MarketBeat
- Cytek Biosciences (CTKB): Evaluating Valuation After TIME's 2026 Growth Leaders Recognition and Recurring Revenue Momentum [Yahoo! Finance]Yahoo! Finance
- TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026 [Yahoo! Finance]Yahoo! Finance
- TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026GlobeNewswire
- Cytek Biosciences (NASDAQ:CTKB) had its price target lowered by analysts at Piper Sandler from $8.00 to $7.50. They now have an "overweight" rating on the stock.MarketBeat
CTKB
Earnings
- 11/5/25 - Beat
CTKB
Sec Filings
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- CTKB's page on the SEC website